

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.



## STANDARD CHARTERED PLC

渣打集團有限公司

(Incorporated as a public limited company in England and Wales with limited liability)

(Registered Number: 966425)

(Stock Code: 02888)

### COMPANY INFORMATION SHEET

This information sheet is published pursuant to Rule 19.60 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (**the “HK Listing Rules”**) and is provided for the purpose of giving information to the public about Standard Chartered PLC (**the “Company”**) as at the date of this information sheet. The information does not purport to be a complete summary about the Company and/or its securities.

#### Summary of Novel Waivers

The following are the novel waivers granted to the Company:

<b>Relevant Rule Waived</b>	<b>Subject Matter</b>
Rules 10.06(2)(d), (3), (4) and (5) of the HK Listing Rules	<p><b>Waiver from disclosure requirements for share repurchases of the Company on the London Stock Exchange</b></p> <p>Rule 10.06(2)(d) provides that an issuer shall procure any broker it appointed to effect the repurchase of its shares to disclose to the Stock Exchange of Hong Kong Limited (<b>“the Exchange”</b>) such information with respect to share repurchases made on behalf of the issuer as the Exchange may request.</p> <p>A waiver was granted to the Company such that Rule 10.06(2)(d) would not apply to repurchases of shares made by the Company on the London Stock Exchange.</p> <p><b>Waiver from restrictions on subsequent issues and reporting requirements on repurchases of preference shares of the Company</b></p> <p>Rules 10.06(3) to (5) set out the restrictions on the subsequent issues of shares following share repurchases, the reporting requirements for the repurchased shares and the requirement that any shares repurchased by the Company must be cancelled.</p> <p>A waiver was granted from strict compliance with Rules 10.06(3), (4) and (5) in respect of the Company’s repurchases of preference shares, subject to the following conditions:</p> <ul style="list-style-type: none"> <li>(i) the repurchases must be made in accordance with all applicable legal requirements in the United Kingdom (<b>“UK”</b>) and UK Listing Rules; and</li> <li>(ii) the Company must disclose in its annual report details of its repurchases made during the financial year under review.</li> </ul>

<p>Rule 10.06(5) of the HK Listing Rules</p>	<p><b>Treasury shares waiver</b></p> <p>Rule 10.06(5) states that shares repurchased by an issuer shall be automatically cancelled.</p> <p>This waiver was granted to the Company in respect of Rule 10.06(5), which provides that any shares repurchased by the Company must be automatically cancelled. This waiver allows the Company, following any repurchase of shares, to elect to hold its own shares in treasury as opposed to having to cancel those shares automatically. This is subject to certain conditions, including compliance by the Company with applicable laws and regulations in the UK (including the UK Listing Rules) in relation to holding shares in treasury.</p> <p>As a result of the Rule 10.06(5) waiver granted to the Company, certain Listing Rules have been modified to show how the relevant Listing Rules will be changed. These modifications were last updated in March 2022 and were posted on the Exchange’s website for reference.</p>
<p>Rule 13.36(1) of the HK Listing Rules</p>	<p><b>Authority to issue Equity Convertible Additional Tier 1 (“ECAT1”) Securities</b></p> <p>Rule 13.36(1) requires that shareholders' approval shall be obtained prior to an issue of convertible securities except as set out under Rule 13.36(2)(b).</p> <p>The waiver was granted to the Company from compliance with Rule 13.36(1) to allow the Company to seek a specific mandate (<b>the “Mandate”</b>) for the issue of ECAT1 Securities. The waiver was granted to the Company subject to the following conditions:</p> <ul style="list-style-type: none"> <li>(i) the Company must announce the waiver before seeking the Mandate; and</li> <li>(ii) the Company must clearly indicate in the announcement and circular relating to the Mandate and the waiver that the Mandate is in addition to the general mandate under Rule 13.36(2).</li> </ul> <p>As a result of the Rule 13.36(1) waiver granted to the Company, the Company obtained a specific mandate from the shareholders in the annual general meeting held on 4 May 2022, for the sole purpose of issuing ECAT1 Securities.</p>
<p>Part XV of the SFO (other than Divisions 5, 11 and 12)</p>	<p><b>Partial exemption from compliance with Part XV of the Securities and Futures Ordinance (“SFO”)</b></p> <p>Part XV of the SFO imposes duties of disclosure of interests in ordinary shares of the Company. Pursuant to section 309(2) of the SFO, the Securities and Futures Commission (“SFC”) granted a partial exemption to the Company, its substantial shareholders, directors and chief executives from compliance with the requirements of Part XV of the SFO (other than Divisions 5, 11 and 12 of Part XV) to notify their interests in securities of the Company and for the Company to prepare registers and maintain records.</p> <p>This partial exemption was granted on conditions that:</p> <ul style="list-style-type: none"> <li>(i) the Company must file with the Exchange any disclosure of interests made in the UK as soon as practicable on the basis that the Exchange will publish these disclosures in the same way as those it receives from other listed corporations pursuant to Part XV; and</li> <li>(ii) the Company shall advise SFC if there is any material change in any of the information given to the SFC, including any significant change to the disclosure requirements in the UK or the Company’s average daily share turnover attributable to trading in Hong Kong exceeding 20%.</li> </ul>

28 June 2022

As at the date of this announcement, the Board of Directors of the Company comprises:

*Chairman:*

José María Viñals Iñiguez

*Executive Directors:*

William Thomas Winters, CBE and Andrew Nigel Halford

*Independent Non-Executive Directors:*

Shirish Moreshwar Apte; David Philbrick Conner; Byron Elmer Grote; Christine Mary Hodgson, CBE (Senior Independent Director); Gay Huey Evans, CBE; Maria da Conceicao das Neves Calha Ramos; Philip George Rivett; David Tang; Carlson Tong and Jasmine Mary Whitbread